340B Program
Commercial Payer 340B Reimbursement Policy Changes
Medicare and commercial payers are simultaneously squeezing 340B drug program margins.
Renata Szymborska
· 10 min read
Buy and Bill Brief — Page 2
Infliximab Biosimilar Reimbursement Benchmark Analysis
Biosimilar reimbursement rates are driving infusion practices toward financial losses.
Jerome Castellano
Why Automation-Only RCM Fails Infusion Platforms at Scale
Payer behavior, not internal operations, now drives infusion revenue loss.
Jerome Castellano
Due Diligence on Infusion RCM Operations in PE Acquisitions
Fragmented infusion RCM creates hidden revenue leaks that standard due diligence misses.
Mei-Lin Tsou
Biosimilar Reimbursement Rates vs Reference Biologic Spread
Medicare's reimbursement formula penalizes biosimilars priced below their reference drugs.
Mei-Lin Tsou
Infusion Group Acquisition Valuation and Revenue Cycle Quality
Buyers must audit billing infrastructure, not just revenue, to value infusion practices correctly.
Mei-Lin Tsou
Payer Contract Reimbursement Rate Benchmarks for Infusion Centers
Distinguish three benchmark types to avoid missing underpayments in infusion contracts.
Renata Szymborska
Infusion Practice EBITDA Margin Benchmarks by Operating Model
Margin, not revenue, determines whether an infusion practice survives.
Mei-Lin Tsou